Stifel Nicolaus Starts CymaBay Therapeutic (CBAY) at Buy
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/1/2026
- Wall Street ends lower as higher yields, rising oil prices mark shaky start to September
- Oil prices jump 4% as fresh US-Iran fighting stokes supply fears
- Two Saudi tankers struck in Strait of Hormuz Monday
- Dell again lifts annual forecasts as AI demand powers record results
- Fed’s Barr backs rate hike if inflation fails to cool, September odds hit 66%
Roth Capital Starts CymaBay Therapeutic (CBAY) at Buy
September 19, 2014 6:45 AM EDTRoth Capital initiated coverage on CymaBay Therapeutic (NASDAQ: CBAY) with a Buy rating and a price target of $14.00.
For an analyst ratings summary and ratings history on CymaBay Therapeutic click here. For more ratings news on CymaBay Therapeutic click here.
Shares of CymaBay Therapeutic closed at $7.38 yesterday.
... More